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There is an urgent need for technologies to prevent sexual
acquisition of HIV infection in young women in sub-Saharan
Africa. After two decades of 11 pivotal trials of seven products,
anti-retroviral-based topical microbicides are showing promise.
Building on the CAPRISA 004 trial findings, several trials of new
anti-viral agents, novel delivery mechanisms and combination/
multipurpose products that address challenges of adherence and
meet the sexual and reproductive health needs of men and
women, including preventing HIV infection, are underway.
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What are microbicides?
Microbicides are vaginally or rectally applied chemical
products designed to prevent the sexual acquisition of HIV.
Similar to the range of available fertility control options, an
array of microbicides will possibly be available in the future
that could be formulated as gels, creams, suppositories, films,
sponges, tablets, physical barriers, implants and vaginal
rings, that would enable men and women to choose products
that suit them best at a particular time in their life course to
meet their sexual and reproductive health needs.
Why is the development of
microbicides important?
Since 2001, substantial progress in slowing the HIV epi-
demic has been made globally, with a 33% decline in the
number of new HIV infections from 3.4 million in 2001 to
2.3 million in 2012.1 The majority of new HIV infections
are taking place in five key populations; young women in
southern Africa, transgender and men who have sex with
men (MSM) in Africa, North America and Latin America,
injecting drug users in Eastern Europe, male and female
sex workers, and prisoners throughout the world. The
scale-up and access to anti-retroviral therapy has drastically
reduced AIDS-related mortality between 2005 and 2012.1
Anti-retroviral therapy has also been shown to have the
added benefit of preventing transmission of HIV in discor-
dant couples2 and use of anti-retroviral drugs by HIV-in-
fected pregnant women intrapartum and postpartum has
virtually eliminated vertical transmission of HIV in some
parts of the world.3 Daily use of anti-retrovirals as
pre-exposure prophylaxis (PrEP) by HIV-uninfected indi-
viduals has also been shown in clinical trials to reduce
acquisition of HIV among serodiscordant couples, MSM
and injection drug users.4–6 Together with existing preven-
tion options, these advances provide new hope for control
of the HIV epidemic.
Despite these successes, the development of microbicides
remains an important goal, especially for populations most
severely affected by the HIV epidemic. For example, in
sub-Saharan Africa, while women account for 60% of all
HIV infections, young women aged 15–24 years represent
76% of the total cases. In addition to the high burden of
HIV infection, young women typically acquire HIV infec-
tion 5–7 years earlier than their male counterparts7,8 and
HIV infections among women can be as much as eight-fold
higher than in men of the same age.9 This age–sex differ-
ence in HIV acquisition patterns between men and women
is a consequence of young women partnering with older




men and is an important driver of the epidemic in this
region.10 Reducing the high infection rates among young
women is key to controlling the epidemic in this region.
Unfortunately, young women have limited ability to imple-
ment the current and new HIV prevention options that are
dependent on use by their sexual partner. Microbicides
therefore fill an important gap in HIV prevention options
for young women and will be central to achieving the goal
of an AIDS-free generation.
Furthermore, microbicides could also be used rectally
and have the potential to expand the HIV prevention
options available to men who have sex with men (MSM)
and meet the needs of women who participate in anal sex.
In countries like the USA, bisexual and other MSM are
more severely affected by HIV than any other group. In
2010, 63% of all new HIV infections occurring in the USA
were among MSM, yet they account for only 4% of the
total male population in the USA.11 New HIV infections
are increasing most rapidly among young black MSM
between the ages of 13 and 24 years. Between 2008 and
2010 there was a 22% increase in new HIV infections in
this population group.11
History of microbicide effectiveness
trials
Clinical trials of surfactants
Over the past 20 years of microbicide development, 11
advanced clinical trials of seven candidate products (some
tested as multiple doses and formulations) have been com-
pleted. The first microbicide candidate tested for its HIV
prevention potential was an existing licensed vaginal con-
traceptive known as nonoxynol-9 (Advantage 24; Columbia
Research Laboratories, Rockville Center, NY, USA). This
product was categorised as a surfactant and inactivated
pathogens, including HIV, in the lumen of the vagina by
disrupting cell surfaces. Sponge, film and gel formulations
of nonoxynol-9 were assessed12–14 but none of these were
shown to reduce the acquisition of HIV. In fact, the gel
formulation of nonoxynol-9 was actually shown to be
harmful and almost doubled the risk of HIV infection
among women who used more than 3.5 applicators per
day.12 Another surfactant, SAVVY (C31G, Cellegy Phar-
maceuticals Inc., Huntingdon Valley, PA, USA), was
assessed in two separate trials in Africa and although it was
shown to be safe, it did not prevent HIV acquisition.15,16
Given the disappointing clinical trial results with surfac-
tants, these products are no longer considered viable candi-
dates for HIV prevention.
Clinical trials of blockers
Products that interfere with the attachment of HIV to the
host cells (blockers) were the next category of microbicide
candidates assessed. These included cellulose sulphate
(UshercellTM; Polydex Pharmaceuticals, Nassau, Bahamas),
Carraguard (product number PDR98-15; FMC, Philadel-
phia, PA, USA), and PRO 2000. The cellulose sulphate
trial was halted prematurely because an interim analysis
suggested that the product may have increased the risk of
acquiring HIV.17 Final analysis, however, showed that cellu-
lose sulphate had no effect on HIV acquisition.17 Carra-
guard was shown to be safe but had no impact on HIV—
HIV incidence was 3.3 per 100 woman-years in the Carra-
guard group and 3.8 per 100 woman-years in the placebo
group.18 In 2009, the HPTN 035 study showed a moderate,
although nonsignificant, 33% lower HIV incidence in
women using 0.5% PRO 2000 compared with placebo.19
However, a much larger trial, the MDP 301 trial, subse-
quently showed that 0.5% PRO 2000 had no protective
effect against HIV infection.20
Clinical trials of buffers
Products designed to maintain a healthy vaginal milieu
(buffers) were the next category of microbicides to be
assessed. These products were designed to supplement or
enhance the natural immune defences of the vagina by
helping to maintain a low pH. By maintaining a low pH it
is thought that pathogens that are sensitive to acidic envi-
ronments can be inactivated. The best known product in
this category was BufferGel (ReProtect LLC, Balitmore,
MD, USA), which was tested alongside 0.5% PRO 2000
in the HPTN 035 trial, but also had no impact on HIV
acquisition.19
Clinical trials of anti-retroviral agents
The current category of microbicides that are being
assessed in last-stage clinical trials includes anti-retroviral
agents that inhibit specific steps in the HIV life cycle. These
compounds generally have potent anti-HIV-specific activity
and a long half-life but need to be used correctly and con-
sistently to work. Topical formulations of anti-retrovirals
have the added advantage of acting locally in the genital
tract, resulting in high concentrations of drug at the site of
infection (i.e. the genital tract), and reducing potential sys-
temic adverse effects. Tenofovir gel, developed by Gilead
Sciences, was the first anti-retroviral drug that was shown
to significantly reduce the risk of both HIV and herpes
simplex virus type 2 (HSV-2) acquisition in women. In
2010, the Centre for the AIDS Programme of Research in
South Africa (CAPRISA) 004 tenofovir gel trial showed that
HIV acquisition was reduced by 39% and HSV-2 acquisi-
tion by 51% when tenofovir gel was used before and after
sex.21 Despite these very encouraging results, even with
high levels of adherence, tenofovir gel was shown to pro-
vide only 54% protection21 and in women with detectable
drug levels of >1000 ng/ml tenofovir gel’s effectiveness
54 ª 2014 Royal College of Obstetricians and Gynaecologists
Abdool Karim et al.
reached 74%.22 These findings suggest that other factors
may be contributing to the suboptimal efficacy of tenofovir
gel. Understanding what biological factors could be con-
tributing to the reduced potency of tenofovir gel is impor-
tant. Notwithstanding continued efforts to unravel this
bio-behavioural nexus, modelling these findings demon-
strates that tenofovir gel could potentially avert 1.3 million
new HIV infections and over 800 000 deaths in South
Africa over the next 20 years.23
The optimism that a safe and effective microbicide
would soon be available was dampened by the outcome of
the VOICE (Vaginal and Oral Interventions to Control the
Epidemic) trial. This trial, which evaluated daily dosing of
tenofovir gel, demonstrated an effectiveness level of 14.7%
(95% confidence interval 21 to 40).24 The lack of protec-
tion was primarily due to the low levels of adherence; esti-
mated, based on detectable drug levels, to be 23%.24 The
outcome of the FACTS 001 trial,25 which is currently in
the field across multiple sites in South Africa, that was
designed to confirm the CAPRISA 004 trial findings could
provide the data needed for regulatory approval of tenofo-
vir gel. An open label implementation effectiveness study
(CAPRISA 008) is underway in the communities where the
CAPRISA 004 trial took place and addresses critical imple-
mentation questions about how best tenofovir gel could be
incorporated into current health systems and could pave
the way to more rapid public sector access of a licensed
product.
Microbicide candidates in
development or planned that have
potential to meet multiple sexual and
reproductive health needs
Although there are over 70 microbicide candidates in the
preclinical development pipeline,26 the majority of these
products will never reach clinical trial testing in humans.
The number of products currently in human trials is actu-
ally very limited and includes: probiotics like lactobacilli
and six anti-retroviral agents—tenofovir, dapivirine, marav-
iroc, MIV-150, GSK ‘744 and rilpivirine.
While initial microbicides were evaluated for their anti-
HIV activity as well as for fertility control and prevention
of bacterial sexually transmitted infections, over time the
priority focus was on HIV prevention. With increasing
anti-HIV-specific products in testing and some proof of
concept there has been renewed interest in the development
of co-formulated and co-administered products that are
capable of simultaneously meeting multiple sexual repro-
ductive health needs of women such as HIV risk reduction,
fertility control and treatment of other sexually transmitted
infections. Microbicides that are based on a combination of
products are seen as offering a potential for synergy,
reduced drug resistance and multiple targeting. Although
barrier devices like condoms are considered multipurpose
prevention technologies, only potential microbicide or
PrEP candidates are discussed in this paper.
Lactobacilli, which occur naturally in the vagina and help
to maintain a low pH by secreting lactic acid, are promis-
ing microbicide candidates. Phase 2 studies have demon-
strated that Lactobacillus crispatus (LACTIN-V) is safe and
well tolerated among women with bacterial vaginosis27 and
in a separate study, the product has been associated with a
significant reduction in recurrent uterine tract infections.28
Another promising probiotic candidate is a live recombi-
nant Lactobacillus, L. jensenii, which has been shown in a
macaque model to reduce simian immunodeficiency virus
(SIV) transmission by 63% and may proceed to human
testing soon.29
Tenofovir gel, which was shown to prevent both HIV and
HSV-2,21 is the microbicide in the most advanced stage of
development. In addition to the FACTS 00125 confirmatory
trial and the CAPRISA 008 tenofovir gel implementation
effectiveness trial, a number of trials of tenofovir gel are
ongoing. A rectal safety study of tenofovir 1% gel in young
MSM in the USA and Puerto Rico (Project gel)30 and a
range of pharmacodynamics and pharmacokinetic studies of
various dosing strategies using tenofovir,31 a study of refor-
mulated tenofovir gel for rectal use,32 and a safety study of
tenofovir 1% gel use in pregnant and lactating women33 are
also ongoing. An intravaginal ring containing the tenofovir
disoproxil fumarate prodrug has been developed by
CONRAD. Preclinical studies have been completed and
demonstrate that the tenofovir-containing intravaginal ring
provided complete protection in pigtail macaques after
repeat simian human immunodeficiency virus challenge
over 16 weeks,34 even in the presence of high doses of the
hormonal contraceptive depot medroxyprogesterone35and
the tenofovir ring may soon enter clinical trials.
Besides tenofovir, other anti-retroviral agents being
assessed as candidate microbicides include dapivirine
(TMC120), miraviroc, MIV-150 and rilpivirine (TMC278).
Dapivirine is being developed by the International Partner-
ship for Microbicides (IPM) and is currently being evalu-
ated for efficacy in parallel by IPM and the Microbicide
Trials Network as a monthly vaginal ring.36,37 These
long-acting, slow-release, monthly vaginal rings may poten-
tially improve adherence because they are less dependent
on user compliance compared with oral or gel formula-
tions. A safety and pharmacokinetics study of a vaginal ring
that includes a combination of dapivirine and maraviroc is
currently underway in the USA.38 The combination of mul-
tiple anti-retroviral agents in a single application mirrors
the progressive advances in AIDS treatment regimens that
combine anti-retroviral agents from different classes and
could potentially increase their efficacy.
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The Population Council is developing MIV-150 in com-
bination with zinc acetate, a broad-spectrum anti-viral
agent, in a base of carrageenan for the prevention of HIV
and HSV-2 infection. In macaques, a single dose of this gel
has been shown to provide protection against vaginal SIV
infection for up to 24 hours,39 and a phase 1 trial of this
gel has been completed. The Population Council are also
developing intravaginal rings with combinations of
MIV-150, zinc acetate and the contraceptive levonorgestrel
and human trials of these products are scheduled to start
soon.
Long-acting injectable agents are also being developed
as potential PrEP/microbicide agents. Janssen Research &
Development, LLC (Raritan, NJ, USA) is currently assess-
ing the safety, acceptability, pharmacokinetics and ex vivo
pharmacodynamics of a long-acting formulation of rilpivi-
rine (TMC278), administered intramuscularly monthly, in
men and women.40 GSK1265744 (GSK ‘744), a long-act-
ing integrase inhibitor, is also being developed through a
joint venture between GlaxoSmithKline, (Brentford, Mid-
dlesex, UK) and ViiV Healthcare (Brentford, Middlesex,
UK). GSK ‘744 has been evaluated in phase I trials as a
once monthly injection and has been shown to be well
tolerated.41 It may be possible to co-administer these
long-acting injectable agents with injectable contraceptives.
Several anti-retroviral agents, including tenofovir,
MIV-150, dapivirine, vicriviroc and MK-2048, are being con-
sidered for co-formulation with contraceptives to simulta-
neously prevent unintended pregnancies and HIV. One
challenge in offering dual HIV–fertility control options is the
uncertainty relating to the role of hormonal contraceptives
on HIV acquisition.42 Some studies have shown that women
using injectable hormonal contraception, particularly
Depo-Provera (Pfizer, New York, USA), may be at an
increased risk for HIV acquisition,43,44 yet other studies have
found no association.45,46 With the available evidence, it is
not possible to conclude that hormonal contraceptive use
does or does not increase the risk of HIV acquisition. How-
ever, given the uncertainty of the association between hor-
monal contraceptive use and HIV risk, the use of other
nonhormonal contraceptive options like intrauterine devices
may increase in future clinical trials. Other nonhormonal
contraceptive options are also being considered for combina-
tion with anti-retroviral agents, for example the BioRing.47
Clinical trials are also ongoing or planned to evaluate
the potential of combining a barrier device, for example
the SILCS diaphragm, DuetTM or Device for Vaginal Deliv-
ery (DVD2), with tenofovir and other anti-retroviral
agents.48 Mapp Biopharmaceutical, Inc. (San Diego, CA,
USA) plan to develop a vaginal ring or film that will incor-
porate monoclonal antibodies to prevent HIV and HSV-2
while Osel (Mountain View, CA, USA) are developing a
novel microbicide suppository known as MucoCept that
contains Lactobacillus and cyanovirin-N for the prevention
of HIV, bacterial vaginosis, candidosis and uterine tract
infections.47
Although the development of microbicide candidates
with multiple mechanisms of action and dual purpose
products are already in early clinical trials, no products
have advanced to clinical effectiveness trials. The develop-
ment of products that target multiple sexual and reproduc-
tive health needs face some additional challenges besides
the development of a single product. Specifically, the phar-
macokinetic actions of different chemical compounds may
require different conditions for formulation and release.
Furthermore, drug interaction between two or more active
pharmaceutical ingredients combined in one product could
impact on product safety and efficacy. Ensuring the simul-
taneous release/bio-availability of two or three different
active pharmaceutical ingredients for different indications
will also be challenging. Multipurpose technologies also
face an uncertain regulatory pathway.
Challenges in microbicide
development
The development of a safe and efficacious microbicide
has proved challenging. The field has faced numerous
setbacks and rapid advancement has been hampered by
limited investments in the development of candidate
products for clinical testing, formulation and delivery
method challenges, methodological, ethical and design
challenges, lack of a validated animal model, lack of a
correlate of protection, a limited understanding of mech-
anism of HIV acquisition in the female genital tract,
insufficient advocacy efforts, and uncertainty about user
acceptability and demand. Some of these challenges are
elaborated below.
Financial commitment for microbicide research
and development
Securing sufficient funding and enthusiasm for microbicide
development has always been a challenge and extensive and
sustained investment in research and development is
required if a successful product is to be realised. Although
funding of microbicide research has increased signifi-
cantly over the years, rising from US$168 million in 2005
to US$245 million in 2012, investment still lags far behind
research and development funding for HIV vaccines.49 In
2012, the total global investment for HIV vaccine-related
research and development was US$847 million, 3.5 times
more than microbicides.49 Funding for microbicide
research and development may face additional hurdles in
the future if limited financial resources are redirected to
implementation of PrEP, other HIV prevention strategies,
HIV treatment or other diseases.
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The challenge of adherence
One of the greatest challenges in microbicide development
has been suboptimal adherence to the prescribed dosing
regimen. Recently completed microbicide trials demonstrate
how varying levels of adherence impact on effective-
ness.21,24 Adherence is clearly a huge challenge in the con-
duct of clinical trials and a successful microbicide will
require more than just an efficacious anti-HIV product. A
much better understanding of motivators of adherence and
more objective measures of adherence during a trial are
needed as is a better understanding of what women’s needs
are of a product in relation to dosing strategy and formula-
tion.
Many of the early microbicide trials relied exclusively on
self-reported data for both product use and sexual behav-
iour, which has several limitations.50,51 Dye staining of
applicators was subsequently introduced in some of the tri-
als and although this method was shown to be a reliable
and objective way to assess whether an applicator had been
inserted into the vagina,52 differences in composition of
plastics, dyes and product formulations limit the accuracy
and utility of this method.53 Other novel technologies to
monitor applicator use include the UV light assessment of
vaginal applicators54 and wireless technologies like Wise-
bag.55 Anti-retroviral-based microbicides have made it pos-
sible to measure actual drug concentrations to determine
whether the product has been used or not. The limitation
of this method, however, is that drug concentrations can
usually only be measured at the end of the study to avoid
unblinding and it is not possible to measure adherence in
the placebo group. Furthermore, the measurement of drug
levels as an indicator of compliance will become limited in
the future when anti-retrovirals as PrEP become more
widespread because it will not be possible to know if the
detectable drug levels are from the use of PrEP or from the
product under investigation.
The inclusion of an easily detectable marker in the prod-
uct as well as the placebo to obtain objective measures of
adherence in clinical trials is likely to be required. A breath
test to detect alcohol and ketone metabolites from vaginal
products and condoms that were tagged with esters seems
promising.56,57 One limitation of this approach, however, is
that the product being tested will not be the same as the
one intended to be marketed, which may result in regula-
tory hurdles.
Understanding the vaginal microbiome and
mucosal immunology
Whereas strategies for enhancing adherence through novel
delivery mechanisms of anti-retroviral agents together with
better ways to support and measure adherence are critical,
these efforts need to be complemented with a better under-
standing of HIV acquisition vaginally. The establishment
of, for example, the role of genital58 and systemic59 inflam-
mation and co-infection with other sexually transmitted
infections60 in HIV acquisition could require a different
product development pathway than that used to develop
anti-retroviral therapy for AIDS treatment. A cellular and
immunological analysis of how other biological factors
blunt the potency of anti-retroviral agents will be criti-
cally important for new product development and drug
delivery systems. Empirical studies of breakthrough infec-
tions following prophylactic use of anti-retroviral-based
microbicides that monitor disease progression, viral evolu-
tion and resistance patterns are also urgently needed for
evidence-based decisions on prophylactic use of anti-
retrovirals.
Resistance
A unique challenge related to the use of anti-retrovi-
ral-based microbicides is the concern about the potential
for drug resistance development. Although resistance can-
not develop in people who do not have HIV, it could
potentially develop in individuals who become infected
with HIV and continue taking the prophylactic regimen.
Compared with the use of anti-retrovirals in treatment,
resistance acquired from prophylactic use of anti-retrovirals
is anticipated to be much lower.61 Nevertheless, it is impor-
tant that effectiveness trials of microbicides include assess-
ments of the development of resistance. This empirical
evidence will be invaluable to address this issue definitively.
So far, the PrEP products evaluated have all been tenofo-
vir-based. Tenofovir is also a key first-line therapeutic drug.
This has raised some concern about the use of tenofovir in
therapy and prevention. Therapeutic failure is associated
with the development of resistance and thereby the spread
of resistant viruses, which in turn may compromise the
efficacy of the same drugs (or occasionally, the same class
of drugs) used for prophylaxis. It is not known whether
prophylactic use of anti-retrovirals in individuals who sub-
sequently acquire HIV will compromise their future
anti-retroviral treatment options. Follow-on studies of indi-
viduals who acquire HIV infection after PrEP exposure are
needed to determine whether treatment regimens that con-
tain the PrEP agent compromise therapeutic success. Given
the limited number of drugs currently available for treat-
ment, the option for setting aside a class (or classes) of
anti-retrovirals for use in prevention only is not feasible.
Future study designs for microbicide trials
Conducting placebo-controlled microbicide trials may
become challenging in the future once Truvada (Gilead
Sciences Inc., Foster City, CA, USA; a combination of two
oral anti-retroviral drugs, tenofovir and emtricitabine),
which was recently approved for HIV prevention by the US
Food and Drug Administration (FDA), becomes widely
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available as PrEP.62 Furthermore, if the ongoing FACTS
001 trial confirms the results of the CAPRISA 004 trial then
future microbicide trials may need to include the tenofovir
gel in the comparator arm. The ethics of continuing with
placebo-controlled trials as well as the provision of PrEP as
ancillary care in HIV prevention trials is already being
questioned.63 Trial design options that incorporate an
active agent(s) in the comparator group include either a
superiority trial or noninferiority trial. In a superiority trial,
the hypothesis tested is that the new intervention under
investigation is better, by a clinically relevant amount, than
the comparator.64 The new intervention needs to be even
more potent than an active comparator to show superior-
ity, i.e. higher efficacy. Superiority designs are, however,
much larger, more costly and more logistically challenging
than placebo-controlled trials. With trials to test multipur-
pose prevention technologies, the goal would be to show
that the new technology is not worse than the best available
single technologies. Trials of this nature would be designed
as a noninferiority trial with an active comparator. Nonin-
feriority trials are used when the new intervention is
assumed to have some benefits (e.g. improved safety, low
cost) over the comparator intervention, but has similar
efficacy.65
Noninferiority trials bring additional challenges in data
interpretation. First, any intervention can easily be shown
to be noninferior to a non-effective comparator interven-
tion; whether or not either intervention is superior to pla-
cebo or no intervention.66 The second challenge is that any
effect that dilutes the true efficacy of an intervention in a
trial, such as nonadherence, loss to follow-up or protocol
violations, makes it easier for the two interventions to be
declared equivalent. Further, suboptimal adherence to a
highly efficacious product may be as good as high adher-
ence to a low efficacy product.
Alternate adaptive designs, which bridge the gap between
Phase 2b/3 microbicide effectiveness trials, are also being
considered for future microbicide trials.67 This approach
could increase the efficiency of the trial thereby reducing
its duration. The need for a correlate of protection for HIV
prevention trials analogous to CD4+ T-cell count and viral
load monitoring in HIV treatment is urgently needed, par-
ticularly as newer and novel drugs enter clinical testing and
placebo-controlled trials become more limited.
Microbicides for specific target
populations
Inclusion of adolescents in clinical trials
Given the limited HIV prevention options for adolescent
women, they would be an ideal target population for the
introduction of an effective microbicide for individual and
population level benefit. However, none of the microbicide
studies to date have included this important age group,
making the evaluation of microbicides in this group a high
priority. Notably no topical or oral PrEP trials have dem-
onstrated safety concerns and large numbers of HIV-
infected adolescents are on anti-retroviral treatment. The
first trial of daily tenofovir gel use among 16- and
17-year-old girls (FACTS 002) is planned and will provide
important safety data for the use of microbicides in this
group, paving the way for adolescent girls to have access to
a licensed microbicide.
Microbicides for rectal use
Rectal microbicide development has lagged behind the
development of microbicides for vaginal use but is no less
important. The mucosal surfaces in the rectum are vulnera-
ble to physical damage during sex and potentially increase
the risk of HIV infection. Several surveys indicate that het-
erosexual anal intercourse is far more common than gener-
ally acknowledged68–71 and women who engage in anal
intercourse may be less likely to use condoms and more
likely to engage in risky behaviours.70
Although vaginal microbicide products may also be ben-
eficial if used rectally, the distinct differences between the
vagina and rectum may mean that separate products will
be needed specifically for vaginal or rectal use. With some
candidate microbicide products, formulations specifically
for vaginal or rectal use are already available, such as a low
osmolality tenofovir gel that has been specifically formu-
lated for rectal use. Clinical trials evaluating the safety and
effectiveness of rectal microbicides are under way in MSM
populations30,32 and a number of pharmacodynamic/phar-
macokinetic studies are planned using three rectally applied
tenofovir gel formulations.
Microbicide use during pregnancy
Whereas most multipurpose technologies address fertility
control needs with sexual and reproductive health needs,
many young women also desire pregnancy. The safety of
using microbicides during pregnancy is, therefore, impor-
tant to establish. A safety study using tenofovir 1% gel in
pregnant and lactating women33 was initiated in 2011 and
results are anticipated soon.
Conclusion
Anti-retroviral-based microbicides provide real potential to
influence the course of the HIV epidemic, as they fill an
important gap for women-initiated, anti-HIV-specific pre-
vention methods and could potentially offer an alternative
HIV prevention option for men who have sex with men.
So far, only coitally linked use of tenofovir gel has dem-
onstrated moderate effectiveness in preventing HIV infec-
tion and the findings of a confirmatory trial, FACTS 001,
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are eagerly awaited as an important next step towards licens-
ing of tenofovir gel. Studies of new anti-viral agents, novel
delivery mechanisms, combination/multipurpose products
and the role of biological factors in blunting efficacy of
anti-retroviral agents that address challenges of adherence
and enhance the effectiveness of tenofovir gel are already
underway. These advances in microbicide development have
catalysed renewed interest in multipurpose technologies to
meet the sexual and reproductive health needs of men and
women and efforts to prevent HIV infection.
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